[Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy].

Abstract

A clinical study on cefuzonam (CZON), a new parenteral cephalosporin antibiotic, was performed in 22 patients with acute appendicitis. CZON in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes. In the appendices, concentrations of CZON were 0.066-21.7 micrograms/g in normal or slight catarrhal cases, 0.173-11.7 micrograms/g in moderate phlegmous cases and 0.116-12.1 micrograms/g in serious gangrenous perforated cases. The concentration of CZON in appendixes was not directly proportional to the degree of pathological change of inflammation. 6 patients with acute peritonitis due to perforated appendicitis were treated with CZON of 2 g/day for 5-10 days. The clinical effect was good in 5 cases, fair in 1 case of the above 6. The clinical efficacy rate was 83%. Side effects were not notable in the patients.

• Authors: T Hirayama, M Saitoh
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 44 Issue 9 Pg. 987-92 (Sep 1991) ISSN: 0368-2781 [Print] Japan
• PMID: 1960860 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• cefuzonam
• Ceftizoxime

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Appendicitis (complications)
• Ceftizoxime (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Child
• Female
• Humans
• Infusions, Intravenous
• Intestinal Perforation (complications)
• Male
• Middle Aged
• Peritonitis (drug therapy)
• Rupture, Spontaneous